Unraveling the Function of Epithelial-Mesenchymal Transition (Emt) in Colorectal Cancer: Metastasis, Therapy Response, and Revisiting Molecular Pathways Publisher Pubmed



Sabouni E¹ ; Nejad MM¹ ; Mojtabavi S¹ ; Khoshduz S² ; Mojtabavi M³ ; Nadafzadeh N¹ ; Nikpanjeh N¹ ; Mirzaei S⁴ ; Hashemi M^{5, 6} ; Aref AR⁷ ; Khorrami R⁸ ; Nabavi N⁹ ; Ertas YN^{10, 11} ; Salimimoghadam S¹² Show All Authors Show Affiliations
Source: Biomedicine and Pharmacotherapy Published:2023

Abstract

Colorectal cancer (CRC) is a dangerous form of cancer that affects the gastrointestinal tract. It is a major global health concern, and the aggressive behavior of tumor cells makes it difficult to treat, leading to poor survival rates for patients. One major challenge in treating CRC is the metastasis, or spread, of the cancer, which is a major cause of death. In order to improve the prognosis for patients with CRC, it is necessary to focus on ways to inhibit the cancer's ability to invade and spread. Epithelial-mesenchymal transition (EMT) is a process that is linked to the spread of cancer cells, also known as metastasis. The process transforms epithelial cells into mesenchymal ones, increasing their mobility and ability to invade other tissues. This has been shown to be a key mechanism in the progression of colorectal cancer (CRC), a particularly aggressive form of gastrointestinal cancer. The activation of EMT leads to increases in the spread of CRC cells, and during this process, levels of the protein E-cadherin decrease while levels of N-cadherin and vimentin increase. EMT also contributes to the development of resistance to chemotherapy and radiation therapy in CRC. Non-coding RNAs, such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), play a role in regulating EMT in CRC, often through their ability to “sponge” microRNAs. Anti-cancer agents have been shown to suppress EMT and reduce the progression and spread of CRC cells. These findings suggest that targeting EMT or related mechanisms may be a promising approach for treating CRC patients in the clinic. © 2023 The Authors